Abstract
A 12-year-old male being treated for a high-risk relapsed T-acute lymphoblastic leukemia presented progressive weakness and numbness of both legs after having received a chemotherapy regimen that included bortezomib. Diagnosis of acute Guillain-Barré syndrome-like inflammatory demyelinating polyneuropathy was made following clinical examination, cerebrospinal fluid analysis, electrodiagnostic studies, magnetic resonance imaging, and serum immunoglobulin antibodies to anti-ganglioside. Intravenous immunoglobulin treatment was started, resulting in complete clinical recovery. Although in rare cases, Guillain-Barré syndrome after bortezomib therapy has been reported; this paper suggests that GBS may occur when bortezomib is administered and high‑dose intravenous immunoglobulin lead to a resolution of the symptoms.
| Original language | English |
|---|---|
| Pages (from-to) | 187-192 |
| Number of pages | 6 |
| Journal | Pediatric Hematology and Oncology |
| Volume | 39 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2022 |
| Externally published | Yes |
Keywords
- Bortezomib
- case report
- Guillain-Barré syndrome
- relapsed lymphoblastic leukemia
- Magnetic Resonance Imaging
- Immunoglobulins, Intravenous/therapeutic use
- Bortezomib/adverse effects
- Humans
- Male
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
- Guillain-Barre Syndrome/chemically induced
- Child
Fingerprint
Dive into the research topics of 'Guillain-Barré syndrome after bortezomib therapy in a child with relapsed acute lymphoblastic leukemia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver